With the help of DealForma, we review and analyze the highest-value biopharma deals of 2024.

Deals and funding for cell and gene therapy companies have been muted in the past year compared to recent peaks, but emerging technologies that are advancing treatments for autoimmune diseases and in vivo engineering could reinvigorate the field.

Approvals and progress with nucleic-acid-based drugs continue to drive investment and dealmaking in the field.

Next-generation technology and novel targets continue to drive dealmaking around antibody–drug conjugates in oncology.

Find Therapeutics’ experienced leadership is developing a novel approach to repair myelin damage in multiple sclerosis, often associated with early visual impairment.

With its AI-powered technology platform and proprietary microbe collection, Kapoose Creek Bio is advancing a new wave of neuroactive drugs.

BioCanRx is leading the way in the translation, manufacture and adoption of immunotherapies in Canada to ensure that Canadian patients have access to this powerful therapeutic approach via clinical trials.

The Korea Drug Development Fund supports drug development across all areas of medicine, and here present three companies at the forefront of immunology.

Immunotherapies often fail due to limited response rates or acquired resistance. CNCure Biotech is poised to overcome these problems with a novel bacterial platform to develop treatments for oncology and infectious diseases.

Deliver Biosciences’ platform delivery technology aims to democratize the use of curative therapies by designing nanoparticles that can genetically engineer cells inside patients.

Advance backing of early-stage programs is allowing AbbVie to apply a streamlined approach to support the growth of transformative science, people, and ecosystems.

Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet medical needs.

South Korean nanomedicine company Cenyx Biotech is developing four pipelines of nanozymes for a range of acute and chronic inflammatory diseases. The company’s approach could open a new generation of treatments in immunology and inflammation.